For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Naltrexone Treatment for Prolonged Grief Disorder

Clinical Trial Details

This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.

Key Eligibility: 
  • Open to men and women above the age of 18 who meet diagnostic criteria for prolonged grief disorder

  • Participants must not have any recent history of opioid dependence, liver disease, or currently pregnant

   
Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

James Gang
(215) 356-0697
jmg2016@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2004021873

ClinicalTrials.gov:

NCT04547985

Sponsor:

5R35CA197730-05

Status

Open to Enrollment

Age Group

Adult

Sponsor